Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | The importance of MRD in AML prognosis and therapy

Arnon Nagler • 21 Mar 2022
EBMT 2022
Acute Myeloid Leukemia Leukemia

Arnon Nagler, Chaim Sheba Medical Center, Tel-Aviv, Israel, explains comments on the importance of measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). The prognosis of patients with AML is currently based on MRD detection. Patients that are MRD negative pre-transplant have a much lower relapse rate, which translates to better survival rates. Detection of MRD post-transplant is an indicator of relapse allowing for early intervention and treatment. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals